DaWei Microbiology Completes Pre-A Financing to Advance Digital Molecular Diagnostics Platform

Recently, Beijing DAWEI BIO Technology Co., Ltd. (hereinafter referred to as “DAWEI BIO”) announced the completion of its Pre-A financing round. This round was led by Tsinghua Holdings Jinxin Capital, with Mike Biotechnology Co., Ltd. participating as a follow-on investor. DAWEI BIO is dedicated to the development of digital genetic testing medical devices and their clinical applications. The funds raised will be used for the research and development of multiple innovative molecular diagnostic reagents, the advancement of clinical trials, production line construction, and regulatory registration and filing both domestically and internationally.

Digital PCR is an absolute quantification detection technology based on single-molecule nucleic acid amplification counting, and it is currently a key focus in the development of the molecular diagnostics industry. Building on two decades of microfluidics technology R&D, Professor Du Wenbin from the Institute of Microbiology, Chinese Academy of Sciences, and founder of DAWEI BIO, achieved an independent innovation breakthrough with Interfacial Vibration Droplet Array Technology (DAPCO®). The company has independently designed, developed, and mass-produced the OsciDrop® series of digital PCR instruments, along with compatible consumables and universal reagents.Pioneering the acquisition of patent grants in both China and the United States, it broke the monopoly held by foreign technologies and launched disruptive chip-free integrated digital PCR instruments, along with supporting products and applications.It boasts very broad market prospects both domestically and internationally.

DAWEI BIO boasts an excellent team in management, R&D, and sales operations, a comprehensive international intellectual property portfolio, a revolutionary microfluidics technology platform, and strong commercialization capabilities. DAWEI BIO has achieved phased progress in precise tumor diagnosis, detection of infectious diseases, and multiplex testing for genetically modified components, significantly expanding the applicability and quantitative accuracy of molecular diagnostics.

During the pandemic, DAWEI BIO actively participated in the calibration of nucleic acid reference materials, such as inactivated SARS-CoV-2 viruses, for the National Institutes for Food and Drug Control (NIFDC), providing a critical foundation for the development of high-quality reference materials. DAWEI BIO has established close strategic partnerships with HollySys Group (NASDAQ: HOLI) and Maccura Biotechnology (SZ.300463), injecting strong momentum into stabilizing its product supply chain and promoting clinical adoption. Currently, DAWEI BIO’s digital PCR instruments and associated reagents and consumables have entered stable mass production, and the company has forged extensive collaborations with dozens of Grade III Class A hospitals, testing institutions, biopharmaceutical enterprises, and research institutes across China.

Qingkong Jinxin Capital stated that microfluidic technology at the micrometer scale can be applied to numerous fields within the biotechnology industry. The DAWEI BIO team has accumulated extensive experience and continuously innovated in the field of microfluidics. Leveraging their proprietary interfacial vibration droplet array technology, they have developed the world’s first chip-free, fully automated digital PCR system, enabling high-throughput, closed-system, and cost-effective molecular detection. The product’s technical features are well-defined, demonstrating DAWEI BIO’s strong capability in core technological innovation. We look forward to DAWEI BIO’s future performance in the molecular diagnostics market, as well as in broader markets such as single-cell technology and single-molecule sorting.

Maccura Biotechnology stated that the OsciDrop® digital PCR platform launched by DAWEI BIO features a streamlined operational workflow and a chip-free consumable design, elevating the accessibility of digital PCR to an entirely new level. This advancement holds the potential to truly bring digital PCR technology into clinical practice, providing users with faster and more sensitive detection results while offering patients more precise and affordable testing services. Leveraging Maccura Biotechnology’s profound technical expertise and industrialization capabilities, this collaboration will introduce next-generation molecular diagnostic products in the fields of tumor liquid biopsy and infectious disease pathogen detection. These innovations aim to surpass imported foreign products in emerging market segments, thereby realizing the domestic production of high-end medical devices. Based on its recognition of DAWEI BIO’s professional background and extensive accumulation in microfluidics technology, Maccura Biotechnology looks forward to deepening cooperation to widely apply microfluidics technology across other niche areas of in vitro diagnostics.

On March 28, 2021, at the 18th China Advanced Clinical Laboratory Products Fair (CACLP) held at the Chongqing International Expo Center, DAWEI BIO will unveil its new fully automated digital PCR system. During the concurrent “Liang·Jianyan – The 4th Young Entrepreneurs Forum on In Vitro Diagnostics,” Professor Du Wenbin, founder of DAWEI BIO, will deliver a presentation on “Innovative Applications of Microfluidics Technology in the Field of In Vitro Diagnostics.” You are cordially invited to visit our booth (Booth No. N3-T013)!

DAWEI BIO OsciDrop® Series Digital PCR Instrument

DAWEI BIO is a high-tech innovation enterprise in the field of in vitro diagnostics, driven by microfluidics technology and founded by returnees from overseas studies. The company has been recognized as a Zhongguancun High-Tech Enterprise and a Haidian District "Embryo" Enterprise, ranked among the top three in the medical device category of the Zhongguancun International Frontier Competition, and received the "Beijing New Technology and New Product Certification." Leveraging its long-term accumulation of core microfluidics technologies, DAWEI BIO is dedicated to the independent research and development of innovative life science instruments, medical devices, and reagents, providing next-generation automated, precise, and high-throughput solutions for precision medicine, life science research, and other fields.

QingKong JinXin Capital was established in 2013. Leveraging Tsinghua University’s resources in industry, academia, and research, and adhering to the philosophy of “technology as the foundation, finance as the tool,” the company has deeply cultivated strategic emerging industries and the financial capital market. It has become a significant force driving the synergistic development of industry-finance integration within Tsinghua’s industrial ecosystem. As a professional institution specializing in industrial investment and asset management, it is a member enterprise of Tsinghua Holdings’ QingKong Asset Management Group. To date, the total scale of funds managed by QingKong JinXin Capital exceeds RMB 25 billion. The company has strategically positioned itself in strategic emerging sectors such as integrated circuits, biotechnology, artificial intelligence, energy and environmental protection, intelligent manufacturing, pharmaceuticals and healthcare, and modern education. It has led or assisted in completing major investments and mergers and acquisitions totaling nearly RMB 100 billion, including deals involving Spreadtrum, RDA Microelectronics, Wison Energy, Sound Environmental, OmniVision Technologies, Maxscend Microelectronics, Changyang Technology, Zhiyi Biopharma, Huaqin, Galaxis, and Tianyancha.

Maccura Biotechnology (300463.SZ), established in 1994, is a Chinese listed IVD company specializing in the integrated research and development, manufacturing, sales, and service of clinical in vitro diagnostic products. The company has completed its full industry chain layout, spanning from biological raw materials and medical laboratory products to specialized services. It possesses systematic professional capabilities in the R&D and manufacturing of in vitro diagnostic instruments, reagents, calibrators, and quality control materials. Its product portfolio covers technological platforms including clinical chemistry, immunoassay, POCT, coagulation, transfusion medicine, hematology, urinalysis, molecular diagnostics, and pathology. Through product integration, Maccura meets over 90% of the needs of medical laboratories. With extensive experience in market and channel management, Maccura collaborates with more than 1,300 regional distributors across China. Its domestic end-user customer base exceeds 6,500 institutions, including over 2,800 hospitals at Level II and above, and nearly 1,000 hospitals at Level III and above.